Development Of A Multiplex Quantitative Real-Time PCR (QPCR) Assay For Simultaneous Detection Of Schistosoma Haematobium And High-Risk Human Papillomaviruses

Abstract

Background Female genital schistosomiasis (FGS) and high-risk human papillomavirus (hr-HPV) infections frequently co-occur in sub-Saharan Africa and may jointly contribute to cer- vical carcinogenesis. However, no existing molecular platform enables simultaneous detection of Schistosoma haematobium and hr-HPV from a single cervical specimen. Methods A multiplex quantitative real-time PCR (qPCR) assay targeting the S. haematobium Dra1 repeat and seven hr-HPV genotypes (16, 18, 31, 33, 45, 52, 58) was developed and validated. Analytical performance was assessed using HPV reference plasmids from the International HPV Reference Centre and biobanked S. haematobium DNA from the Centre for Research in Applied Biology (CeRAB), Ghana. Clinical perfor- mance was evaluated using 217 archived cervical swabs from high-risk women enrolled in the CERVIVAL project in rural Ghana. Funding: The author(s) received no specific Results funding for this work. The assay showed a limit of detection of 10 copies/µL for all targets, with no cross- Competing interests: The authors have declared that no competing interests exist. reactivity to non-target HPV genotypes, common uropathogenic bacteria, or Schisto- soma mansoni. In reference panels, positive and negative agreement were 98.2% and Abbreviations: CeRAB, Centre for Research 100% for S. haematobium and 100% for both sensitivity and specificity across all hr-HPV in Applied Biology; CCVP, CERVIVAL Clinical Validation Panel; CI, confidence interval; genotypes. In the 217 high-risk cervical samples, S. haematobium DNA was detected in Ct, cycle threshold; FGS, Female Genital 56.7% (123/217). HPV58 (19.8%), HPV16 (14.7%), and HPV52 (12.4%) were the most Schistosomiasis; ARP, Analytical Reference frequent genotypes. Concordance with visual inspection/microscopy for FGS was 93.6% Panel; HCRP, HPV Clinical Reference Panel; HPV, Human papillomavirus; hr-HPV, high-risk (κ = 0.87), and concordance with a molecular HPV test (ScreenFire HPV) ranged from Human papillomavirus; IHRC, International 90.3% to 99.5% (κ = 0.80–0.95) across HPV channels. The assay identified 11 additional Human Papillomavirus Reference Center; LoD, Limit of detection; NPV, Negative predictive S. haematobium–positive samples that were negative by visual inspection/microscopy. value; NTC/NTCs, non-template control(s); PBS, phosphate-buffered saline; PPV, Positive Conclusions predictive value; qPCR, quantitative real-time polymerase chain reaction; SCRP, S. haema- The multiplex qPCR assay provides a highly sensitive and practical tool for integrated tobium Clinical Reference Panel; STI, sexually detection of S. haematobium and hr-HPV from a single cervical sample. Its compatitransmitted infection; VI, visual inspection; VIA, bility with standard qPCR platforms and strong agreement with established diagnostic Visual inspection with acetic acid; WHO, World Health Organization. methods support its potential use in FGS and cervical cancer screening programmes in resource-limited, co-endemic settings. Author summary In sub-Saharan Africa, millions of women face the dual threat of infections that severely impact reproductive health: a parasitic worm known as Schistosoma haematobium, which causes female genital schistosomiasis, and high-risk types of human papillomavirus, the primary cause of cervical cancer. Growing evi- dence suggests that suffering from both infections simultaneously may increase a woman’s risk of developing cervical cancer. However, health programs current- ly lack a simple method to test for both pathogens using a single clinical sample. To address this gap, we developed a new laboratory test capable of detecting DNA from both the parasite and the virus in a single cervical swab. When we evaluated this tool using samples from women in Ghana, we found it to be highly accurate. By combining these diagnoses into one highly sensitive tool that uses standard laboratory equipment, we can streamline screening programs. This approach reduces testing resources and could potentially allow health workers to identify and treat these conditions earlier, offering a practical solution to help prevent cervical cancer in regions where both diseases are widespread.

Description

Keywords

Citation

Collections

Endorsement

Review

Supplemented By

Referenced By